Int J Technol Assess Health Care. 1992 Fall;8(4):719-34.

A model for evaluating the cost-effectiveness of cholesterol-lowering treatment.

Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G.

Source

University of Pennsylvania.

Abstract

We describe and illustrate the use of a generalizable model for evaluating the cost-effectiveness of alternative cholesterol-lowering treatments. We combine standard incidence-based techniques for measuring the cost of illness with logistic risk functions from the Framingham Heart Study to project, for persons with known coronary risk characteristics, the likelihood of developing coronary heart disease (CHD) over a lifetime as well as a number of related outcomes, including the expected loss of years of life due to CHD, the expected lifetime direct and indirect costs of CHD, and the changes in these outcomes that would result from cholesterol-lowering treatment.

PMID:: 1464491; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

Anticholesteremic Agents

LinkOut - more resources

Medical

Cholesterol - MedlinePlus Health Information

Libraries

LinkOut Holdings

Supplemental Content

Save items

Related citations in PubMed

Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. [Pharmacoeconomics. 2004]
Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
Cook JR, Yin D, Alemao E, Drummond M. Pharmacoeconomics. 2004; 22 Suppl 3:37-48.
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. [Ann Intern Med. 2000]
Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Ann Intern Med. 2000 May 16; 132(10):769-79.
Cost implications of lipid-lowering treatments. [Pharmacoeconomics. 1994]
Cost implications of lipid-lowering treatments.
Reckless JP. Pharmacoeconomics. 1994 Oct; 6(4):310-23.
Review [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO]. [Ned Tijdschr Geneeskd. 1998]
Review [Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].
Simoons ML, Casparie AF. Ned Tijdschr Geneeskd. 1998 Sep 19; 142(38):2096-101.
Review Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease. [Pharmacoeconomics. 1998]
Review Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ, Wilde MI. Pharmacoeconomics. 1998 Aug; 14(2):217-36.

See reviews... See all...

Cited by 2 PubMed Central articles

Review Coronary heart disease policy models: a systematic review. [BMC Public Health. 2006]
Review Coronary heart disease policy models: a systematic review.
Unal B, Capewell S, Critchley JA. BMC Public Health. 2006 Aug 18; 6:213. Epub 2006 Aug 18.
Review Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence. [J Epidemiol Community Health. ...]
Review Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.
van der Weijden T, Knottnerus JA, Ament AJ, Stoffers HE, Grol RP. J Epidemiol Community Health. 1998 Sep; 52(9):586-94.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

A model for evaluating the cost-effectiveness of cholesterol-lowering treatment.
A model for evaluating the cost-effectiveness of cholesterol-lowering treatment.
Int J Technol Assess Health Care. 1992 Fall ;8(4):719-34.

PubMed
Patient-centered communication, ratings of care, and concordance of patient and ...
Patient-centered communication, ratings of care, and concordance of patient and physician race.
Ann Intern Med. 2003 Dec 2 ;139(11):907-15.

PubMed
Clinical correlates of dental anxiety among older adults.
Clinical correlates of dental anxiety among older adults.
Community Dent Oral Epidemiol. 1992 Dec ;20(6):372-5.

PubMed
Integrated strategies to tackle the inequitable distribution of doctors in Thail...
Integrated strategies to tackle the inequitable distribution of doctors in Thailand: four decades of experience.
Hum Resour Health. 2003 Nov 25;1(1):12.

PubMed
The slippery-slope argument.
The slippery-slope argument.
J Clin Ethics. 1992 Winter ;3(4):256-68.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: